Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer

NCT02047513 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

127

Enrollment

OTHER

Sponsor class

Conditions

Resectable Pancreatic Cancer
Ductal Adenocarcinoma of the Pancreas

Interventions

DRUG: perioperative nab-paclitaxel/gemcitabine
DRUG: adjuvant nab-paclitaxel/gemcitabine

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]
[object Object]